Cilgavimab Biosimilar - Research Grade

Human

Severe acute respiratory syndrome coronavirus 2

>1mg/ml

IgG1 - kappa

CHO Cells

Adintrevimab Biosimilar - Research Grade (ICH5329), Amubarvimab Biosimilar - Research Grade (ICH5342), Bebtelovimab Biosimilar - Research Grade (ICH5377), Beludavimab Biosimilar - Research Grade (ICH5385), Canrivitug Biosimilar - Research Grade (ICH5425), Crexavibart Biosimilar - Research Grade (ICH5455), Ensovibep Biosimilar - Research Grade (ICH5528), Etesevimab Biosimilar - Research Grade (ICH5535), Gorivitug Biosimilar - Research Grade (ICH5581), Imdevimab Biosimilar - Research Grade (ICH5598), Lomtegovimab Biosimilar - Research Grade (ICH5654), Masavibart Biosimilar - Research Grade (ICH5672), Nepuvibart Biosimilar - Research Grade (ICH5707), Nisfevitug Biosimilar - Research Grade (ICH5714), Ogalvibart Biosimilar - Research Grade (ICH5725), Pemivibart Biosimilar - Research Grade (ICH5767), Plutavimab Biosimilar - Research Grade (ICH5779), Regdanvimab Biosimilar - Research Grade (ICH5813), Romlusevimab Biosimilar - Research Grade (ICH5834), Simaravibart Biosimilar - Research Grade (ICH5865), Sipavibart Biosimilar - Research Grade (ICH5866), Timcevibart Biosimilar - Research Grade (ICH5923), Tixagevimab Biosimilar - Research Grade (ICH5930), Upanovimab Biosimilar - Research Grade (ICH5958), Vebanvibart Biosimilar - Research Grade (ICH5971)

https://www.imgt.org/mAb-DB/

ICH3002

Blue ice

The SARS-CoV-2 spike glycoprotein drives viral attachment and entry and is a primary antigen for neutralization and infection research. Provided as an unconjugated, non-therapeutic analog of cilgavimab, this human IgG1-kappa recombinant antibody is intended strictly for research use (RUO). It is an ultra-pure, low-endotoxin preparation meeting in vivo standards and produced in scalable milligram-to-gram quantities for heavy-usage, high-throughput virology laboratories. Suitable applications include neutralization and functional assays, spike-binding characterization, in vitro screening and preclinical coronavirus models, with dependable lot-to-lot consistency. Supplied low in endotoxin and built to in vivo standards, it scales from milligram to gram quantities for bulk, reagent-intensive workflows.

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks

Q: Is the Cilgavimab biosimilar available in gram quantities?

A: Yes — it is manufactured in scalable milligram to gram quantities to support bulk and high-throughput preclinical experiments.

Q: Is this research-grade Cilgavimab biosimilar suitable for in vivo studies?

A: Yes, it is supplied in a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Cilgavimab biosimilar target?

A: It is a non-therapeutic research analog of Cilgavimab that recognizes and neutralizes Severe acute respiratory syndrome coronavirus 2; for research use only.